We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DuPont Agrees to Divest Its Aramids Business to Arclin for $1.8B
Read MoreHide Full Article
Key Takeaways
DuPont signed a $1.8B agreement with Arclin to divest its Kevlar and Nomex Aramids business.
The deal brings DuPont $1.2B in cash, a $300M note and a $325M equity stake in Arclin.
The sale supports DuPont's strategic focus while its Qnity spin-off remains on track.
DuPont de Nemours, Inc. (DD - Free Report) has entered into a definitive agreement with Arclin, a portfolio company of an affiliate of TJC, L.P. (TJC), to sell off its Aramids business, including Kevlar and Nomex brands, for approximately $1.8 billion.
The transaction is expected to close in the first quarter of 2026, upon which DuPont will receive $1.2 billion (pre-tax) in cash, subject to adjustments, $300 million in note receivable and a non-controlling equity stake valued at $325 million, representing around 17.5% ownership in the new Arclin entity. The move does not hamper the planned Qnity electronics business spin-off. It remains on schedule for Nov. 1, 2025.
The divestiture is aimed at enhancing the company’s strategic focus and strengthening its financial profile. TJC’s expertise in value creation through an operations-focused approach made it an appropriate choice as a partner. The partnership is expected to drive growth and opportunity for the employees and customers of the combined businesses.
For Arclin, the addition of brands will present an opportunity to expand its global reach and strengthen its position in high-performance market-leading applications. The acquisition will enable Arclin to bring about impactful solutions and products to market.
DD’s Aramids business, as the inventor and largest global producer of industry-leading high-performance synthetic fibers, generated net sales of $1.3 billion in 2024, with about 1,900 employees and five manufacturing sites.
DD stock has lost 4.3% over the past year compared with the industry’s 17.1% decline.
The Zacks Consensus Estimate for AEM’s current-year earnings is pegged at $6.94 per share, implying a 64.07% year-over-year surge. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 10.03%. AEM’s shares have soared 84.8% in the past year.
The Zacks Consensus Estimate for MOS’ 2025 earnings is pegged at $3.17 per share, indicating a rise of 60.10% from year-ago levels. The company’s earnings beat the consensus estimate in one of the trailing four quarters while missing it in the rest. Its shares have gained 25.5% in the past year.
The Zacks Consensus Estimate for CRS’ current fiscal-year earnings is pegged at $9.51 per share, indicating a 27.14% year-over-year increase.Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.38%. CRS’shares have surged 80.4% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DuPont Agrees to Divest Its Aramids Business to Arclin for $1.8B
Key Takeaways
DuPont de Nemours, Inc. (DD - Free Report) has entered into a definitive agreement with Arclin, a portfolio company of an affiliate of TJC, L.P. (TJC), to sell off its Aramids business, including Kevlar and Nomex brands, for approximately $1.8 billion.
The transaction is expected to close in the first quarter of 2026, upon which DuPont will receive $1.2 billion (pre-tax) in cash, subject to adjustments, $300 million in note receivable and a non-controlling equity stake valued at $325 million, representing around 17.5% ownership in the new Arclin entity. The move does not hamper the planned Qnity electronics business spin-off. It remains on schedule for Nov. 1, 2025.
The divestiture is aimed at enhancing the company’s strategic focus and strengthening its financial profile. TJC’s expertise in value creation through an operations-focused approach made it an appropriate choice as a partner. The partnership is expected to drive growth and opportunity for the employees and customers of the combined businesses.
For Arclin, the addition of brands will present an opportunity to expand its global reach and strengthen its position in high-performance market-leading applications. The acquisition will enable Arclin to bring about impactful solutions and products to market.
DD’s Aramids business, as the inventor and largest global producer of industry-leading high-performance synthetic fibers, generated net sales of $1.3 billion in 2024, with about 1,900 employees and five manufacturing sites.
DD stock has lost 4.3% over the past year compared with the industry’s 17.1% decline.
Image Source: Zacks Investment Research
DD’s Zacks Rank & Key Picks
DD currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Agnico Eagle MinesLimited (AEM - Free Report) , The Mosaic Company (MOS - Free Report) and Carpenter Technology Corporation (CRS - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for AEM’s current-year earnings is pegged at $6.94 per share, implying a 64.07% year-over-year surge. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 10.03%. AEM’s shares have soared 84.8% in the past year.
The Zacks Consensus Estimate for MOS’ 2025 earnings is pegged at $3.17 per share, indicating a rise of 60.10% from year-ago levels. The company’s earnings beat the consensus estimate in one of the trailing four quarters while missing it in the rest. Its shares have gained 25.5% in the past year.
The Zacks Consensus Estimate for CRS’ current fiscal-year earnings is pegged at $9.51 per share, indicating a 27.14% year-over-year increase.Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.38%. CRS’shares have surged 80.4% in the past year.